Ensuring Product Integrity

𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗿𝘀 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗔𝗜 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝘀 — 𝗮𝗿𝗲 𝘆𝗼𝘂 𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗮𝗯𝗼𝘂𝘁 𝗶𝗻𝘁𝗲𝗴𝗿𝗶𝘁𝘆? Not just performance, UX or monetization — but ℎ𝑜𝑤 𝑦𝑜𝑢𝑟 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑐𝑎𝑛 𝑏𝑒 𝑚𝑖𝑠𝑢𝑠𝑒𝑑, 𝑚𝑖𝑠𝑢𝑛𝑑𝑒𝑟𝑠𝑡𝑜𝑜𝑑, 𝑜𝑟 𝑐𝑎𝑢𝑠𝑒 𝑢𝑛𝑖𝑛𝑡𝑒𝑛𝑑𝑒𝑑 ℎ𝑎𝑟𝑚. With AI baked into everything from search to avatars to chatbots, integrity is no longer “someone else’s problem.” It’s a product decision. Here’s questions to ask when shipping AI-based tools: 🔍 What’s the worst use case someone could try here? 🧒 What happens if a 14-year-old uses this — or misuses it? 🌏 Have we tested this in non-English or non-Western contexts? 🚦 Is there a clear fallback if the model behaves unpredictably? 📢 Can we explain how this output was generated? Because 𝐀𝐈 𝐝𝐨𝐞𝐬𝐧’𝐭 𝐛𝐫𝐞𝐚𝐤 𝐭𝐡𝐞 𝐬𝐚𝐦𝐞 𝐰𝐚𝐲 𝐟𝐨𝐫 𝐞𝐯𝐞𝐫𝐲𝐨𝐧𝐞. 𝐈𝐭 𝐛𝐫𝐞𝐚𝐤𝐬 𝐢𝐧 𝐬𝐮𝐛𝐭𝐥𝐞, 𝐜𝐮𝐥𝐭𝐮𝐫𝐚𝐥, 𝐚𝐧𝐝 𝐜𝐨𝐧𝐭𝐞𝐱𝐭-𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐰𝐚𝐲𝐬. 🧭 Safety and integrity aren’t blockers. They’re enablers of responsible scale. #ProductManagement #AISafety #TrustAndSafety #AIIntegrity #TechInAsia #PlatformSafety #ResponsibleAI

𝗗𝗮𝘁𝗮 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗶𝘀𝗻'𝘁 𝗮 𝘀𝗶𝗻𝗴𝗹𝗲 𝗰𝗵𝗲𝗰𝗸 －it's a continuous contract enforced across the various data layers to avoid breakage. Think about it. Planes don’t just fall out of the sky when they land. Crashes happen when people miss the little signals that get brushed off or ignored. Same thing with data. Bad data doesn’t shout; it just drifts quietly—until your decisions hit the ground. When you bake quality checks into every layer and, actually use observability tools, You end up with data pipelines that hold up. Even when things get messy. That’s how you get data people can trust. Why does this matters? Bad data costs money → Failed ML models, wrong decisions. Good monitoring catches 90% of issues automatically. → Raw Materials (Ingestion)  • Inspect at the dock before accepting delivery.  • Check schemas match expectations. Validate formats are correct.  • Monitor stream lag and file completeness. Catch bad data early.  • Cost of fixing? Minimal here, expensive later.  • Spot problems as close to the source as you can. → Storage (Raw Layer)  • Verify inventory matches what you ordered.  • Confirm row counts and volumes look normal.  • Detect anomalies: sudden spikes signal upstream issues.  • Track metadata: schema changes, data freshness, partition balance.  • Raw data is your backup plan when things go sideways. → Processing (Transformation)  • Quality control during assembly is critical.  • Validate business rules during transformations. Test derived calculations.  • Check for data loss in joins. Monitor deduplication effectiveness.  • Statistical profiling reveals outliers and distribution shifts.  • Most data disasters start right here. → Packaging (Cleansed Data)  • Final inspection before shipping to warehouse.  • Ensure master data consistency across all sources.  • Validate privacy rules: PII masked, anonymization works.  • Verify referential integrity and temporal logic.  • Clean doesn’t always mean correct. Keep checking. → Distribution (Published Data)  • Quality assurance for customer-facing products.  • Check SLAs: freshness, availability, schema contracts met.  • Monitor aggregation accuracy in data marts.  • ML models: detect feature drift, prediction degradation.  • Dashboards: validate calculations match source data.  • Once data is published, you’re on the hook. → Cross-Cutting Layers (Force Multipliers)  • Metadata: rules, lineage, ownership, quality scores  • Monitoring: freshness, volume, anomalies, downtime  • Orchestration: dependencies, retries, SLAs  • Logs: failures, patterns, early warning signs Honestly, logs are gold. Don’t sleep on them. What's your job? Design checkpoints, not firefight data incidents. Quality is built in, not inspected in. Pipelines just 𝗺𝗼𝘃𝗲 data. Quality 𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝘀 your decisions. Image Credits: Piotr Czarnas 𝘌𝘷𝘦𝘳𝘺 𝘭𝘢𝘺𝘦𝘳 𝘯𝘦𝘦𝘥𝘴 𝘪𝘯𝘴𝘱𝘦𝘤𝘵𝘪𝘰𝘯.  𝘚𝘬𝘪𝘱 𝘰𝘯𝘦, 𝘳𝘪𝘴𝘬 𝘦𝘷𝘦𝘳𝘺𝘵𝘩𝘪𝘯𝘨 𝘥𝘰𝘸𝘯𝘴𝘵𝘳𝘦𝘢𝘮.

Three Inspectors Walk into a Cleanroom… and see the same deviation three different ways. Inside an aseptic suite, an operator adjusts a bioreactor’s pH, then records it much later, after the action. The value is correct. The batch is safe. But the timestamp is late. That single entry becomes a mirror of how the world defines control. ⸻ 🇺🇸 FDA Investigator — “Show me control.” To the FDA, timing is trust. A backdated entry breaks ALCOA (data integrity principle). They’ll expect root cause, CAPA effectiveness, and management oversight. Their mindset: prove you’re in control, not just compliant. ⸻ 🇪🇺 EU Inspector — “Prove product integrity.” How did this deviation clear Qualified Person release? They’ll trace governance: procedures, cross-checks, and QP assurance. Their mindset: the system failed upstream of the QP signature. ⸻ 🇯🇵 PMDA Inspector (査察官) — “Assure reliability and harmony.” They study the workflow itself: operator training, procedural flow, cultural fit. The focus isn’t punishment but prevention. Their mindset: reliability is built through harmony between process and people. ⸻ Same deviation. Three perspectives. Because GMPs may be harmonized on paper, but interpretation lives in culture. ⸻ 💡 Leadership Lesson Great leaders don’t design just for one agency, they design for intent. Quality systems must satisfy multiple expectations: 1️⃣ Proof (FDA) 2️⃣ Oversight (EU/QP) 3️⃣ Consistency (Japan) The question isn’t who’s right, it’s whether your system speaks the language of trust. ⸻ 💬 If three inspectors walked in tomorrow, would your system speak one language of trust — or three dialects of compliance? Which dialect do you find hardest to align? Subscribe to The Beacon Brief — once a month, always free: 📬 https://lnkd.in/gNXeXDzH

As information security practitioners, we are entrusted with the critical responsibility of protecting the confidentiality, integrity, and availability (CIA) of data. While each component of the CIA triad is essential, today I want to focus on the importance of INTEGRITY and why it must never be overlooked.  Confidentiality ensures that sensitive information is accessed only by authorised personnel. Availability guarantees that the information and systems are accessible to those who need them when they need them. INTEGRITY ensures that data remains accurate, consistent, and trustworthy throughout its lifecycle. It is the foundation upon which critical decisions are made, from patient care to financial transactions. When integrity is compromised, the consequences can be devastating. Take the tragic case of the Therac-25 medical radiation incidents. 💉 Between 1985 and 1987, six patients suffered severe radiation overdoses due to a combination of software bugs and design flaws in the Therac-25 machine. These incidents highlight the dire consequences of failing to maintain the integrity of systems and data. Read more about the incident here: https://lnkd.in/gey8kk4c To uphold integrity, consider these actionable steps: 🔶 Tighten access controls and authentication mechanisms 🔶Rigorously test and validate systems before any update goes live—lessons learned from Therac-25 🔶 Establish Secure System Configurations (system hardening, regular patches, monitor systems, etc.) 🔶 Deploy Detective Controls (system audits, file integrity checkers, and antivirus systems to identify and alert on unauthorised changes) 🔶 Establish clear incident response and recovery procedures  🔶And importantly, cultivate a culture of integrity. Set the standard high and lead by example, emphasising integrity in every decision In the private sector, compromised integrity can lead to financial losses, reputational damage, and legal liabilities. Imagine the chaos that would ensue if a bank's transaction records were altered or corrupted. In the public sector, the stakes are even higher. Inaccurate or tampered data could lead to miscarriages of justice, compromised national security, or erosion of public trust.  #IntegrityMatters #CIATriad #InfoSecEssentials

Data Integrity is not a documentation activity. It is the foundation of every GMP decision. In pharmaceutical operations, every batch release, OOS investigation, stability conclusion, validation decision, regulatory submission, and Quality judgement depends on one simple question: Can we trust the data? Data Integrity means data must remain: ✅ Attributable – who did it, when, and why ✅ Legible – readable and understandable ✅ Contemporaneous – recorded at the time of activity ✅ Original – first capture or verified true copy ✅ Accurate – scientifically correct and truthful ✅ Complete – including raw data, metadata, repeats, re-runs and audit trails ✅ Consistent – logical sequence of events and timestamps ✅ Enduring – protected throughout the retention period ✅ Available – retrievable for review, investigation and inspection But in real GMP environments, Data Integrity goes far beyond ALCOA+. It includes: 🔹 validated computerized systems 🔹 controlled access and unique user IDs 🔹 audit trail review 🔹 secure backup and archival 🔹 controlled spreadsheets 🔹 good documentation practices 🔹 traceable laboratory raw data 🔹 investigation of missing, altered, repeated or unexplained data 🔹 risk-based governance 🔹 training and accountability 🔹 leadership-driven quality culture A strong Data Integrity program is built on three pillars: People – trained, ethical, accountable users Process – controlled SOPs, reviews, investigations and CAPA Technology – validated, secure, traceable systems Weak data integrity does not only create inspection risk. It creates decision risk. Because when data is incomplete, manipulated, poorly reviewed, overwritten, backdated, selectively reported or not traceable, the organization may lose confidence in: ❌ test results ❌ batch release decisions ❌ stability trends ❌ method validation conclusions ❌ deviation investigations ❌ product quality assurance The real maturity of a GMP organization is visible in how it handles data when nobody is watching. Do people record in real time? Do reviewers challenge unusual results? Are audit trails actually reviewed? Are invalid tests scientifically justified? Are repeated errors trended? Does management create a culture where people can report mistakes without fear? Data Integrity is a culture before it becomes a checklist. It is not about creating more documents. It is about creating trustworthy records, reliable systems, ethical behaviors, and scientifically defensible decisions. Data is not just information. Data is evidence. Data is accountability. Data is patient safety. #DataIntegrity #Pharma #GMP #QualityAssurance #ALCOA #ALCOAPlus #CSV #AuditTrail #21CFRPart11 #Annex11 #GoodDocumentationPractices #QualityCulture #RegulatoryCompliance #OOS #OOT #CAPA #Validation #PharmaceuticalIndustry

𝗪𝗵𝘆 𝗮 𝗦𝗲𝗰𝘂𝗿𝗲 𝗮𝗻𝗱 𝗖𝗼𝗻𝘀𝗶𝘀𝘁𝗲𝗻𝘁 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗮𝗻𝗻𝗮𝗯𝗶𝘀 𝗦𝘂𝗽𝗽𝗹𝘆 𝗖𝗵𝗮𝗶𝗻 𝗜𝘀 𝗩𝗶𝘁𝗮𝗹 𝗳𝗼𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝗮𝗳𝗲𝘁𝘆 In medical cannabis, consistency is not a luxury, it is a clinical requirement. When a patient relies on a specific product to control pain, anxiety, epilepsy, or any other condition, the stability of that product is fundamental to their treatment. A secure supply chain underpins this stability, yet it is often the most overlooked part of the industry. The most successful pharmaceutical systems in the world rely on predictable, validated, & repeatable supply chains. Medical cannabis should be no different. If the raw material changes from one batch to the next, the patient experience changes with it. When there are delays, stock-outs, or last-minute substitutions, the impact is felt directly by the people who rely on these medicines every day. A secure supply chain ensures several critical outcomes. It makes consistent cannabinoid & terpene profiles across every batch, allowing clinicians to prescribe confidently & patients to trust the product they receive. It reduces the risk of contamination, mislabelling, or degradation during transport & storage. It also ensures that each step of the process, from cultivation to processing to packaging, is carried out under audited & compliant conditions. The consequences of an insecure supply chain are significant. Patients can experience sudden changes in efficacy, unexpected side effects, or a complete loss of therapeutic benefit. Clinics face reputational harm, pharmacists struggle with unpredictable stock, & regulators lose confidence in the system. Ultimately, when supply chain integrity fails, patient safety is compromised. A strong supply chain is built on three pillars. The first is cultivation partners who follow GACP & produce stable, validated genetics. The second is processing facilities operating under EU GMP, delivering pharmaceutical-grade consistency. The third is a logistics pathway that protects product integrity & ensures uninterrupted supply. The industry must recognise that competition based solely on price is short-sighted. Medical cannabis must be treated with the same seriousness as any other medicine, where quality, consistency, & reliability define the value. Companies that prioritise secure supply chains earn trust, build long-term partnerships, & ultimately deliver better outcomes for patients. If we want medical cannabis to stand shoulder to shoulder with established therapies, then the industry must commit to stable, secure, & compliant supply chains. This is not only good practice, it is an ethical obligation to the patients who depend on us. If you would like support strengthening your supply chain, auditing your partners, or validating your products from seed to sale, I can assist with a full review of your operations and compliance readiness. Note: Picture is not real and made for illustration purposes only.

🔬 Understanding Tablet Defects in Pharmaceutical Manufacturing In solid-dosage manufacturing, the quality of compressed tablets is a critical determinant of product safety, efficacy, and patient acceptability. Despite advances in process engineering, tablet defects remain a significant challenge due to the complex interactions between formulation variables, material attributes, and equipment parameters. Some of the most commonly observed defects include: 1️⃣ Capping and Lamination These defects occur when the tablet separates horizontally, either partially (capping) or completely (lamination). They often result from entrapped air, inadequate compression force, or improper tooling conditions. Material properties such as poor plasticity or high elastic recovery can exacerbate these issues. 2️⃣ Picking and Sticking Picking happens when material adheres to the engraved punches, while sticking involves adhesion to the punch faces. It is typically associated with high moisture content, low melting point APIs, or insufficient lubricant distribution. Proper die wall lubrication and optimized temperature/humidity control are essential to prevent this. 3️⃣ Weight Variation and Hardness Failure Inconsistent powder flow, segregation of active and excipients, and poor die fill lead to weight variability, ultimately affecting content uniformity. Similarly, hardness inconsistencies may arise from non-uniform compression profiles or fluctuations in feed frame dynamics. 4️⃣ Chipping and Cracking These mechanical defects arise due to brittle formulations, excessive drying, or weak inter-particulate bonding. They can compromise tablet integrity during packaging, transportation, and handling. 5️⃣ Mottling and Color Variation Uneven distribution of colorants, thermal instability of dyes, and improper blending can result in aesthetic defects like mottling—an important visual quality attribute assessed during final Q.C. --- 🧪 Ensuring Quality Through Process Control Minimizing tablet defects requires a holistic approach that integrates: ✔ Material characterization (flowability, compressibility, moisture behavior) ✔ Robust formulation design ✔ Advanced process controls such as PAT, real-time analytics, and granulation optimization ✔ Preventive maintenance of compression tooling and equipment In modern pharmaceutical manufacturing, applying Quality by Design (QbD) principles and understanding critical process parameters (CPPs) and critical material attributes (CMAs) is key to achieving consistent tablet quality and reducing defect rates. #PharmaceuticalManufacturing #TabletDefects #PharmaQuality #QualityAssurance #QualityControl #PharmaEngineering #SolidDosageForms #GMP

Cleaning validation is a documented, systematic process proving that manufacturing equipment cleaning procedures consistently remove residues (product, cleaning agents, microbes) to safe, acceptable levels, preventing cross-contamination and ensuring future product quality and patient safety, especially critical in pharmaceuticals. It's about having documented proof that equipment is truly clean, not just visually clean, meeting regulatory standards like GMP. Key Aspects: Purpose: To prevent contamination, ensure product purity, and protect patient health. What it removes: Previous product ingredients (APIs), excipients, detergents, microorganisms, dust, and endotoxins. Process: Document: Define the cleaning method and set strict acceptance limits (e.g., health-based limits). Test: Use methods like swabbing (direct) or rinsing (indirect) to sample surfaces. Analyze: Chemically test samples for residues. Verify: Confirm the process consistently meets criteria. Regulatory Requirement: A fundamental part of Good Manufacturing Practices (GMP) in pharma, medical devices, and related industries. Methods: Includes visual inspection, swab tests, rinse sampling, and TOC (Total Organic Carbon) analysis. In simple terms: It's the scientific proof that a cleaning method works every single time, ensuring the next batch of medicine isn't tainted by the last once

Cleaning Validation:- It is a documented process of proving that cleaning procedures consistently and effectively remove residues from pharmaceutical manufacturing equipment to acceptable levels. This is critical for ensuring product quality, preventing cross-contamination between different batches or products, and meeting regulatory requirements like those from the FDA and EMA. Validation confirms that cleaning removes residues of active pharmaceutical ingredients (APIs), cleaning agents, and microbial contaminants, ensuring patient safety and product purity. Why it's important? Patient safety: It prevents the dangerous risk of contamination from previous products, cleaning agents, or microbes. Product quality: It ensures that subsequent products manufactured on the same equipment are not compromised by residues from previous batches. Regulatory compliance: It is a mandatory aspect of Good Manufacturing Practices (GMP) required by regulatory bodies like the FDA and EMA. Prevents cross-contamination: It ensures that different products can be made on the same equipment without the risk of one product contaminating another. What it involves? Developing a protocol: A formal document outlining the entire validation process, including objectives, scope, responsibilities, cleaning procedures, and acceptance criteria. Setting acceptance criteria: Establishing the maximum allowable residue limits for both the product and the cleaning agents. Performing the cleaning: Following the approved cleaning procedure, which includes selecting appropriate cleaning agents, using specific rinse times and water quality, and paying close attention to hard-to-clean areas. Sampling: Collecting samples from the cleaned equipment using methods like rinse or direct sampling to test for residues. Analytical testing: Analyzing the samples with sensitive methods to measure residue levels and confirm they are below the established acceptance criteria. Documentation: Thoroughly documenting every step of the process, from the initial protocol to the final report, to provide a complete record. Validation vs. verification Cleaning Validation: A one-time process to prove that the cleaning method works. It is performed initially and when significant changes are made to the process. Cleaning Verification: A routine, ongoing process performed after each cleaning cycle to confirm that a specific cleaning run has met the established cleanliness criteria.